nach oben

Erschienen in:

30.07.2022 | COVID-19 | IM-ORIGINAL

To clarify the safety profile of paracetamol for home-care patients with COVID-19: a real-world cohort study, with nested case–control analysis, in primary care

verfasst von: Francesco Lapi, Ettore Marconi, Ignazio Grattagliano, Alessandro Rossi, Diego Fornasari, Alberto Magni, Pierangelo Lora Aprile, Claudio Cricelli

Erschienen in: Internal and Emergency Medicine | Ausgabe 8/2022

Einloggen, um Zugang zu erhalten

Abstract

Background and objective

This study aimed to compare the prescribing patterns of paracetamol in COVID-19 with those for similar respiratory conditions and investigated the association between paracetamol use and COVID-19-related hospitalization/death.

Methods

Using a primary care data source, we conducted a cohort study to calculate the incidence rate of paracetamol use in COVID-19 and for similar respiratory conditions in 2020 and 2019 (i.e. pre-pandemic phase), respectively. In the study cohort, we nested a case–control analyses to investigate the association between paracetamol use and COVID-19-related hospitalizations/deaths.

Results

Overall, 1554 (33.4 per 1000) and 2566 patients (78.3 per 1000) were newly prescribed with paracetamol to treat COVID-19 or other respiratory conditions, respectively. Those aged 35–44 showed the highest prevalence rate (44.7 or 99.0 per 1000), while the oldest category reported the lowest value (17.8 or 39.8 per 1000). There was no association for early (OR = 1.15; 95% CI: 0.92–1.43) or mid-term (OR = 1.29; 95% CI: 0.61–2.73) users of paracetamol vs. non-users. Instead, the late users of paracetamol showed a statistically significant increased risk of hospitalization/death (OR = 1.75; 95% CI: 1.4–2.2).

Conclusions

Our findings provide reassuring evidence on the use and safety profile of paracetamol to treat early symptoms of COVID-19 as in other respiratory infections.

Nur mit Berechtigung zugänglich

Elliott J, Whitaker M, Bodinier B et al (2021) Predictive symptoms for COVID-19 in the community: REACT-1 study of over 1 million people. PLOS Med 18:e1003777. https://doi.org/10.1371/JOURNAL.PMED.1003777CrossRefPubMedPubMedCentral

Dinnes J, Deeks JJ, Berhane S et al (2021) Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD013705.PUB2CrossRefPubMedPubMedCentral

Home care for patients with suspected or confirmed COVID-19 and management of their contacts. https://www.who.int/publications/i/item/home-care-for-patients-with-suspected-novel-coronavirus-(ncov)-infection-presenting-with-mild-symptoms-and-management-of-contacts. Accessed 21 Feb 2022

NICE Overview | COVID-19 rapid guideline: managing COVID-19 | Guidance | NICE. https://www.nice.org.uk/guidance/ng191. Accessed 20 Feb 2022

CDC Treatments Your Healthcare Provider Might Recommend if You Are Sick | CDC. https://www.cdc.gov/coronavirus/2019-ncov/your-health/treatments-for-severe-illness.html. Accessed 20 Feb 2022

AIFA Medicines usable for treatment of COVID-19 disease | Italian Medicines Agency. https://www.aifa.gov.it/en/aggiornamento-sui-farmaci-utilizzabili-per-il-trattamento-della-malattia-covid19. Accessed 22 Feb 2022

DrI DG, A R et al (2021) How to treat COVID-19 patients at home in the Italian context: an expert opinion. Infect Dis Rep. https://doi.org/10.3390/IDR13010028CrossRef

Tuccori M, Convertino I, Ferraro S et al (2020) The impact of the COVID-19 “Infodemic” on drug-utilization behaviors: implications for pharmacovigilance. Drug Saf 43:699–709. https://doi.org/10.1007/S40264-020-00965-WCrossRefPubMedPubMedCentral

Enners S, Gradl G, Kieble M et al (2021) Utilization of drugs with reports on potential efficacy or harm on COVID-19 before, during, and after the first pandemic wave. Pharmacoepidemiol Drug Saf 30:1493–1503. https://doi.org/10.1002/pds.5324CrossRefPubMedPubMedCentral

10.

Pandolfi S, Simonetti V, Ricevuti G, Chirumbolo S (2021) Paracetamol in the home treatment of early COVID-19 symptoms: a possible foe rather than a friend for elderly patients? J Med Virol 93:5704–5706 CrossRefPubMedPubMedCentral

11.

Suter F, Consolaro E, Pedroni S et al (2021) A simple, home-therapy algorithm to prevent hospitalisation for COVID-19 patients: a retrospective observational matched-cohort study. EClinicalMedicine 37:100941CrossRefPubMedPubMedCentral

12.

Dimova S, Hoet PHM, Dinsdale D, Nemery B (2005) Acetaminophen decreases intracellular glutathione levels and modulates cytokine production in human alveolar macrophages and type II pneumocytes in vitro. Int J Biochem Cell Biol 37:1727–1737. https://doi.org/10.1016/J.BIOCEL.2005.03.005CrossRefPubMed

13.

Pandolfi S, Chirumbolo S, Ricevuti G et al (2022) Home pharmacological therapy in early COVID-19 to prevent hospitalization and reduce mortality: time for a suitable proposal. Basic Clin Pharmacol Toxicol 130:225–239. https://doi.org/10.1111/bcpt.13690CrossRefPubMed

14.

Battaggia A Un algoritmo terapeutico domiciliare per prevenire i ricoveri? I risultati possono essere dovuti a sbilanciamento e a errore random - E&P Repository. https://repo.epiprev.it/index.php/download/un-algoritmo-terapeutico-domiciliare-per-prevenire-i-ricoveri-i-risultati-possono-essere-dovuti-a-sbilanciamento-e-a-errore-random/. Accessed 21 Feb 2022

15.

Prada L, Santos DC, Baião RA et al (2021) Risk of SARS-CoV-2 Infection and COVID-19 Severity Associated With Exposure to Nonsteroidal Anti-Inflammatory Drugs: Systematic Review and Meta-Analysis. J. Clin, Pharmacol

16.

Faillie JL (2015) Indication bias or protopathic bias? Br J Clin Pharmacol 80:779–780. https://doi.org/10.1111/BCP.12705CrossRefPubMedPubMedCentral

17.

Tamim H, Tahami Monfared AA, LeLorier J (2007) Application of lag-time into exposure definitions to control for protopathic bias. Pharmacoepidemiol Drug Saf 16:250–258. https://doi.org/10.1002/PDS.1360CrossRefPubMed

18.

Vaja R, Chan JSK, Ferreira P et al (2021) The COVID-19 ibuprofen controversy: a systematic review of NSAIDs in adult acute lower respiratory tract infections. Br J Clin Pharmacol 87:776–784. https://doi.org/10.1111/BCP.14514CrossRefPubMed

19.

Lawrenson R, Williams T, Farmer R (1999) Clinical information for research; the use of general practice databases. J Public Health Med 21:299–304CrossRefPubMed

20.

Bianchini E, Brignoli O, Cricelli C VIII Report Health Search. Available at: http://healthsearch.it/documenti/Archivio/Report/VIIIReport_2013-2014/index.html.

21.

Lapi F, Domnich A, Marconi E et al (2021) Predicting the risk of severe COVID-19 outcomes in primary care: development and validation of a vulnerability index for equitable allocation of effective vaccines. Expert Rev Vaccines. https://doi.org/10.1080/14760584.2022.2019582CrossRefPubMed

22.

Lapi F, Simonetti M, Michieli R et al (2012) Assessing 5-year incidence rates and determinants of osteoporotic fractures in primary care. Bone. https://doi.org/10.1016/j.bone.2011.09.048CrossRefPubMed

23.

Guglielmi V, Bellia A, Pecchioli S et al (2016) What is the actual epidemiology of familial hypercholesterolemia in Italy? Int J Cardiol, Evidence from a National Primary Care Database. https://doi.org/10.1016/j.ijcard.2016.08.269CrossRef

24.

Cricelli C, Mazzaglia G, Samani F et al (2003) Prevalence estimates for chronic diseases in Italy: exploring the differences between self-report and primary care databases. J Pub Health Med 25:254–257CrossRef

25.

Breslow NE (1996) Statistics in epidemiology: the case-control study. J Am Stat Assoc. https://doi.org/10.1080/01621459.1996.10476660CrossRefPubMed

26.

Collins GS, Reitsma JB, Altman DG, Moons KGM (2015) Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. J Clin Epidemiol 68:134–143. https://doi.org/10.1016/j.jclinepi.2014.11.010CrossRefPubMed

27.

Orsini N, Bellocco R, Bottai M et al (2008) A tool for deterministic and probabilistic sensitivity analysis of epidemiologic studies. Stata J 8:29–48CrossRef

28.

Hempenius M, Groenwold RHH, de Boer A et al (2021) Drug exposure misclassification in pharmacoepidemiology: sources and relative impact. Pharmacoepidemiol Drug Saf 30:1703–1715. https://doi.org/10.1002/pds.5346CrossRefPubMedPubMedCentral

29.

30.

Pandolfi S, Chirumbolo S (2021) Home therapy of COVID-19 at the earliest may greatly prevent hospitalization. Basic Clin Pharmacol Toxicol 129:395–396. https://doi.org/10.1111/bcpt.13650CrossRefPubMedPubMedCentral

31.

Mitchell JR, Jollows DJ (1975) Metabolic activation of drugs to toxic substances. Gastroenterology 68:392–410. https://doi.org/10.1016/S0016-5085(75)80025-4CrossRefPubMed

32.

Kennon-McGill S, McGill MR (2018) Extrahepatic toxicity of acetaminophen: critical evaluation of the evidence and proposed mechanisms. J Clin Transl Res 3:297–310PubMed

33.

Ranstam J (2016) Multiple P-values and Bonferroni correction. Osteoarthr Cartil 24:763–764. https://doi.org/10.1016/j.joca.2016.01.008CrossRef

34.

Schneeweiss S (2006) Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 15:291–303. https://doi.org/10.1002/pds.1200CrossRefPubMed

35.

Collie S, Champion J, Moultrie H et al (2022) Effectiveness of BNT162b2 vaccine against omicron variant in South Africa. N Engl J Med 386:494–496. https://doi.org/10.1056/NEJMC2119270/SUPPL_FILE/NEJMC2119270_DISCLOSURES.PDFCrossRefPubMed

Titel: To clarify the safety profile of paracetamol for home-care patients with COVID-19: a real-world cohort study, with nested case–control analysis, in primary care
verfasst von: Francesco Lapi
Ettore Marconi
Ignazio Grattagliano
Alessandro Rossi
Diego Fornasari
Alberto Magni
Pierangelo Lora Aprile
Claudio Cricelli
Publikationsdatum: 30.07.2022
Verlag: Springer International Publishing
Schlagwort: COVID-19
Erschienen in: Internal and Emergency Medicine / Ausgabe 8/2022
Print ISSN: 1828-0447
Elektronische ISSN: 1970-9366
DOI: https://doi.org/10.1007/s11739-022-03054-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

To clarify the safety profile of paracetamol for home-care patients with COVID-19: a real-world cohort study, with nested case–control analysis, in primary care